Abstract:The aim of the present study is to identify novel promising marks and targets of diagnosis, therapy and prognosis for patients with vestibular schwannoma at the molecular level. The gene expression profiles of GSE54934, GSE39645 and GSE56597 datasets were obtained respectively from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) were identified by comparing between gene expression profiles of the vestibular schwannoma tissues and normal tissues. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and protein-protein interaction (PPI) network analysis were performed. The function and pathway enrichment analysis were performed for DEGs with DAVID. Reverse transcription-quantitative PCR were conducted to confirm the expression of BCL2, AGT, IL6 and ITGA2 in human Schwann cells and vestibular schwannoma cells. A total of 4,025, 1,1291 and 1,513 DEGs were identified from GSE54934, GSE56597 and GSE39645 datasets, respectively. GO and KEGG analysis showed that the mutual upregulated genes were mainly enriched in cell division, mitotic nuclear division, and transition of mitotic cell cycle, whilst mutual downregulated genes were enriched in chemical synaptic transmission, neurotransmitter transport, and synaptic vesicle membrane. Subsequently, 20 genes, including BCL2, AGT, IL6 and ITGA2 were selected as hub genes with high degrees after PPI network analysis. The significant differential expression of those genes were detected among vestibular schwannoma tissues compared with normal nerve tissues. In conclusion, BCL2, AGT, IL6 and ITGA2 are significantly higher expressed in vestibular schwannoma tissues compared with human Schwann tissues. The DEGs identified in the present study provide novel targets for the diagnosis and treatment of vestibular schwannoma.

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

Biomarkers in Vestibular Schwannoma–Associated Hearing Loss

Molecular pathogenesis of vestibular schwannomas: insights for the development of novel medical therapies

Untreated Vestibular Schwannoma: Analysis of the Determinants of Growth

Correlation of Immunomodulatory Cytokines with Tumor Volume and Cerebrospinal Fluid in Vestibular Schwannoma Patients

Predictors of Vestibular Schwannoma Growth and Clinical Implications

Identification of Factors Associated with Tinnitus Outcomes Following the Microsurgical Treatment of Vestibular Schwannoma Patients

Study on tinnitus-related electroencephalogram microstates in patients with vestibular schwannomas

Protein Profiling of Cerebrospinal Fluid from Patients Undergoing Vestibular Schwannoma Surgery and Clinical Significance

A Review of Drug Therapy in Vestibular Schwannoma

Identification of Key Biomarkers and Immune Infiltration in Sporadic Vestibular Schwannoma Basing Transcriptome-Wide Profiling

Single-cell Transcriptomes Reveal the Heterogeneity and Microenvironment of Vestibular Schwannoma.

Single-Cell RNA-Seq Reveals Heterogeneity of Cell Communications between Schwann Cells and Fibroblasts within Vestibular Schwannoma Microenvironment

Identification Of Predictive Proteins And Biological Pathways For The Tumorigenicity Of Vestibular Schwannoma By Proteomic Profiling

Identification of Differentially Expressed miRNAs and mRNAs in Vestibular Schwannoma by Integrated Analysis.

Tumor biomechanical stiffness by magnetic resonance elastography predicts surgical outcomes and identifies biomarkers in vestibular schwannoma and meningioma

Tmic-31. Molecular Prognostic Factors Of The Progression Of Vestibular Schwannoma After Primary Tumor Resection

Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery: Otologists’ Perspective from Bedside to Bench

Development of a 23-Gene Signature for Tumor Growth Mechanism in Vestibular Schwannoma

Identification of Key Pathways and Genes in Vestibular Schwannoma Using Bioinformatics Analysis.

Β 2 -Microglobulin Participates in the Development of Vestibular Schwannoma by Regulating Nuclear Factor-κB.